Incidence of dementia · Older people living in the community
Multi‐domain interventions showed no clear difference in incidence of dementia compared with usual care/placebo (high certainty).
1 finding from 1 review
Incidence of MCI · Older people living in the community
Multi‐domain interventions showed no clear difference in incidence of MCI compared with usual care/placebo (moderate certainty).
1 finding from 1 review
Cognitive decline · Older people living in the community
3 findings from 1 review
no estimate extracted
3 studies · 4617 participants
High
no estimate extracted
6 studies · 8697 participants
Moderate
no estimate extracted
2 studies · 1554 participants
Very low
All‐cause mortality · Older people living in the community
Multi‐domain interventions showed no clear difference in mortality compared with usual care/placebo (high certainty).
1 finding from 1 review
Recurrence of any episodes at one year (hospitalization for any episodes) · bipolar disorder
1 finding from 1 review
Recurrence of manic episode at one year · bipolar disorder
Lamotrigine showed no clear difference in recurrence of manic episode at one year compared with placebo (moderate certainty).
1 finding from 1 review
Recurrence of depressive episode at one year · bipolar disorder
Lamotrigine showed no clear difference in recurrence of depressive episode at one year compared with placebo (moderate certainty).
1 finding from 1 review
Health status and quality of life · bipolar disorder
1 finding from 1 review
Total severity score from depression and mania symptom scores, such as HDRS and the YMRS · bipolar disorder
1 finding from 1 review
Recurrence of any episodes at one year (Young Mania Rating Scale (YMRS) total score ≥15 for manic episode) · bipolar disorder
Lamotrigine may leads to lower recurrence of any episodes at one year (Young Mania Rating Scale… compared with placebo (low certainty).
1 finding from 1 review
Recurrence of any episodes at one year (Montgomery‐Asberg Depression Rating Scale (MADRS) total score ≥15 for depressive episode; Hamilton Depression Rating Scale (HDRS) total score ≥14 for depressive episode) · bipolar disorder
Lamotrigine showed no clear difference in recurrence of any episodes at one year (Montgomery‐Asberg Depression… compared with placebo (low certainty).
1 finding from 1 review
Recurrence of any episodes at one year for clinical worsening with additional psychotropics (mood stabilizers, antidepressants, antipsychotics or benzodiazepines) · bipolar disorder
Lamotrigine probably leads to lower recurrence of any episodes at one year for clinical worsening with… compared with placebo (moderate certainty).
1 finding from 1 review
Recurrence of any episodes at one year (active suicidal behavior) · bipolar disorder
1 finding from 1 review
no estimate extracted
1 study · 1 participants
GRADE not reported
Treatment withdrawal · bipolar disorder
It is very uncertain whether lamotrigine changes withdrawal from treatment due to any reason, up to 12 weeks after… compared with placebo (very low certainty).
1 finding from 1 review
Withdrawal from treatment due to any reason, 6‐12 months after intervention initiation (long term) · bipolar disorder
Lamotrigine probably leads to lower withdrawal from treatment due to any reason, 6‐12 months after… compared with placebo (moderate certainty).
1 finding from 1 review
Any reported adverse effects up to 12 weeks after starting treatment (short term) · bipolar disorder
It is very uncertain whether lamotrigine changes any reported adverse effects up to 12 weeks after starting treatment… compared with placebo (very low certainty).
1 finding from 1 review
Any reported adverse effects 6‐12 months after initiating the intervention (long term) · bipolar disorder
Lamotrigine showed no clear difference in any reported adverse effects 6‐12 months after initiating the… compared with placebo (moderate certainty).
1 finding from 1 review
Death due to any cause · adults with mild to severe COVID‐19
Hydroxychloroquine (HCQ) showed no clear difference in death due to any cause compared with standard care or placebo (high certainty).
1 finding from 1 review
Participants with any adverse events · people who have been exposed to SARS‐CoV‐2
Hydroxychloroquine (HCQ) probably leads to higher participants with any adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Participants with serious adverse events · people who have been exposed to SARS‐CoV‐2
1 finding from 1 review